Proginova dragees 2 mg 21 pcs

Proginova contains estrogen – estradiol valerate, which is converted in the human body in the natural 17β-estradiol. While taking proginova suppression of ovulation does not occur, and practically does not change the secretion of hormones in the body.

Estradiol restores estrogen deficiency in the female body after menopause and provides effective treatment of the psycho-emotional and autonomic menopausal symptoms (such as hot flushes, sweating, insomnia, irritability, irritability, palpitations, cardialgia, dizziness, headache, decreased libido, muscle and joint pain); involution of the skin and mucous membranes, especially the mucous membranes of the urogenital system (urinary incontinence, dryness and irritation of the vagina, pain during sexual intercourse).

HRT with an adequate dose of estrogen, such as occurs in proginova reduces bone resorption and retards or stops bone loss in postmenopausal women. It has been shown that long-term use of hormone replacement therapy (HRT) can reduce the risk of peripheral bone fractures in women after menopause. When canceling HRT rates of decrease in bone mass comparable to those typical for the period immediately following menopause. Is no evidence that using HRT, it is possible to achieve restoration of bone mass to premenopausal levels.

HRT also has a beneficial effect on the collagen content of the skin, as well as its density, and can also slow down the formation of wrinkles.

HRT leads to lower total cholesterol, low density lipoprotein cholesterol (LDL) and increasing high density lipoprotein cholesterol (HDL) and triglyceride levels increase. The addition of progestogen may to some extent interfere with the effects of estradiol metabolism. In general, the metabolic effects of HRT is viewed as positive and it is believed that they are involved in reducing the risk of cardiovascular disease in postmenopausal women.

Women with no hysterectomy, when applying proginova recommended supplementation progestogen for at least 10 days per cycle. This reduces the risk of endometrial hyperplasia and the attendant risk of adenocarcinoma in women in this group.

Active substance:
Estradiol

Manufacturer

Delfarm S.A.S. Lille, France

Prescribing

For women, for women in menopause, for postmenopausal women, adults on prescription

Composition

1 tablet contains:

The active ingredient is:

valerat2 mg estradiol;

Excipients:

lactose monohydrate 46 – 250 mg;

corn starch 26 – 200 mg;

povidone 25000 – 3 mg;

Talc – 2.4 mg;

magnesium stearate – 0.15 mg;

crystalline sucrose 33 – 540 mg;

povidone 700000 – 0.323 mg;

Macrogol 6000 – 3,719 mg;

precipitated calcium carbonate 14 – 572 mg;

talc – 7.104 mg;

glycerol 85% (w / w) – 0,205 mg;

titanium dioxide (E171, S.1.77891) – 0.411 mg;

indigo carmine (E132, S.1.73015) – 0,051 mg;

wax montaglycol – 0,075 mg.

Indications

Osteoporosis in menopause

Hormone replacement therapy (HRT) for climacteric disorders, involutive changes skin and genitourinary tract, depressive states in climacteric and symptoms of estrogen deficiency due to natural menopause or sterilization;

prevention of postmenopausal osteoporosis.

Contraindications

• pregnancy;
• lactation;
• vaginal bleeding of unknown origin;
• confirmed or suspected breast cancer;
• confirmed or suspected premalignant disease or hormone-hormone dependent cancers;
• liver tumors now or in the past (benign or malignant);
• severe liver disease;
• acute arterial thrombosis or thromboembolism (such as myocardial infarction, stroke);
• deep vein thrombosis in the acute stage, thromboembolism present or in the past;
• the presence of a high risk of venous and arterial thrombosis;
• severe hypertriglyceridemia;
• congenital lactase deficiency, sucrase / isomaltase, lactose intolerance, glucose-galactose malabsorption;
• childhood and adolescence to 18 years;
• hypersensitivity to the drug Proginova.

Side effects

In rare cases – headache, nausea, stomach disorders function, breast tenderness, weight change, uterine bleeding, chloasma.

How to accept, acceptance rate and dosage

Inside, after eating, with liquid squeezed small amount of liquid, 1 tablet daily for 21 days, then – a break of 7 days.

In the presence of menstruation should be Proginova on the 5th day of menstrual bleeding.

In any other case, the possibility of immediate treatment recommended by a doctor.

When you save the uterus possible additional appointment of another hormone – progesterone. And the need for a doctor recommendation: whether or not to take pills continuously (without interruption), or intermittently.

The time of day reception Proginova does not matter. However, if the first pills taken at a certain time of the day, to be followed this time and when receiving all future tablets.

Storage conditions

At a temperature of not higher than 30 ° C.

Active substance

Estradiol